BACKGROUND This study aimed to identify the clinical background and treatment outcomes of risk-reducing salpingo-oophorectomy (RRSO) in Japan for women with hereditary breast and ovarian cancer (HBOC). METHODS In the present retrospective observational study, we examined the Japanese HBOC Consortium's (JHC) database. This database contains 11,711 probands who received BRCA genetic testing, or their relatives, with any cancer in 2433 pedigrees. This study was supported by the registration committee of the JHC. RESULTS We analyzed 488 individuals diagnosed with HBOC, of which 153 (31.4%) underwent RRSO. Of the latter patients, 88 carried BRCA1 mutation (B1); 62 carried BRCA2 mutation (B2); and 3 carried both mutations. During a mean follow-up period of 2.6 years (range 0-12.6), one patient developed a primary peritoneal cancer (PPC). Clinical background comparison for individuals who underwent RRSO vs. those > 45 years of age who did not undergo RRSO revealed that significant factors were represented by B1 (p < 0.0001); child bearing (p < 0.00001); and breast cancer history (p < 0.01). However, family history of ovarian cancer and menopause status were not significantly different. CONCLUSION Over 30% HBOC's in Japan underwent RRSO. In Japan, individuals with breast cancer history and B1 generally underwent RRSO, whereas those who did not bear a child mostly avoided RRSO.

中文翻译：

---

日本遗传性乳腺癌和卵巢癌降低风险的输卵管卵巢切除术的临床背景和结果。

背景技术本研究旨在确定遗传性乳腺癌和卵巢癌（HBOC）妇女在日本的降低风险的输卵管卵巢切除术（RRSO）的临床背景和治疗结果。方法在本回顾性观察研究中，我们检查了日本HBOC联盟（JHC）的数据库。该数据库包含11,711名接受BRCA基因检测的先证者或其亲属，有2433个血统的癌症。这项研究得到了JHC注册委员会的支持。结果我们分析了488名被诊断患有HBOC的患者，其中153名（31.4％）接受了RRSO。在后者中，有88名携带BRCA1突变（B1）；62个携带BRCA2突变（B2）；和3携带两个突变。在平均2.6年的随访期间（范围0-12.6），一名患者患上了原发性腹膜癌（PPC）。对接受RRSO的个体与> 45岁且未接受RRSO的个体进行的临床背景比较显示，重要因素以B1表示（p <0.0001）。子轴承（p <0.00001）; 和乳腺癌病史（p <0.01）。但是，卵巢癌的家族史和更年期状态没有显着差异。结论日本有超过30％的HBOC接受了RRSO。在日本，具有乳腺癌病史和B1的个体通常接受RRSO，而那些没有生育孩子的人则大多避免使用RRSO。卵巢癌家族史和更年期状态无明显差异。结论日本有超过30％的HBOC接受了RRSO。在日本，具有乳腺癌病史和B1的个体通常接受RRSO，而那些没有生育孩子的人则大多避免使用RRSO。卵巢癌家族史和更年期状态无明显差异。结论日本有超过30％的HBOC接受了RRSO。在日本，具有乳腺癌病史和B1的个体通常接受RRSO，而那些没有生育孩子的人则大多避免使用RRSO。